Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Arrowhead Pharmaceuticals  / Equity Bottom-Up

<ul>
<li>Arrowhead Pharmaceuticals reported its fiscal third quarter results for 2026, highlighting significant developments primarily centered on plozasiran and its expansion potential.</li>
<li>The company announced positive top-line Phase III data from the SHASTA-3 and SHASTA-4 trials in severe hypertriglyceridemia (sHTG), with both studies meeting primary and all prespecified secondary endpoints.</li>
<li>Median triglyceride reductions were 79% and 81%, respectively, demonstrating deep and durable effects.</li>
</ul>


Arrowhead Pharmaceuticals reported its fiscal third quarter results for 2026, highlighting significant developments primarily centered on plozasiran and its expansion potential.
The company announced positive top-line Phase III data from the SHASTA-3 and SHASTA-4 trials in severe hypertriglyceridemia (sHTG), with both studies meeting primary and all prespecified secondary endpoints.
Median triglyceride reductions were 79% and 81%, respectively, demonstrating deep and durable effects.


Arrowhead Pharmaceuticals & Madrigal — Strategic Partnerships Broaden The RNAi Growth Engine!

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>In this report we analyzed data from technical publications to review leadership in RNA related therapeutics. We have listed the top thirty.</li>
<li>In terms of quantity and quality of innovations <a href="https://www.smartkarma.com/entities/alnylam-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:2191:1" rel="noopener">Alnylam Pharmaceuticals (ALNY US)</a>  and <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna (MRNA US)</a>  are best positioned. Among private companies Senda Biosciences screened well. </li>
<li>Partnerships and acquisitions  between RNA startups and big pharma as well as between big pharma and big pharma highlight RNA's potential versatility, risks and the necessity for RNA related exposure.</li>
</ul>


In this report we analyzed data from technical publications to review leadership in RNA related therapeutics. We have listed the top thirty.
In terms of quantity and quality of innovations Alnylam Pharmaceuticals (ALNY US)  and Moderna (MRNA US)  are best positioned. Among private companies Senda Biosciences screened well. 
Partnerships and acquisitions  between RNA startups and big pharma as well as between big pharma and big pharma highlight RNA's potential versatility, risks and the necessity for RNA related exposure.


Who Are Leading the Charge in the RNAissance of Medicine

<ul>
<li>Arrowhead Pharmaceuticals is progressing through a pivotal transitional phase marked by the recent commercial launch of REDEMPLO, an FDA-approved RNAi-based therapy for familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by extremely elevated triglyceride levels.</li>
<li>The U.S. launch initiated in late 2025 has gained traction, with over 400 prescriptions written within approximately five months and a patient base predominantly naive to similar APOC3 inhibitors.</li>
<li>The company’s pricing strategy—set at a wholesale acquisition cost (WAC) of $45,000 annually, a premium over competitors—is supported by clinical data signaling superior triglyceride reduction, safety, and dosing convenience.</li>
</ul>


Arrowhead Pharmaceuticals is progressing through a pivotal transitional phase marked by the recent commercial launch of REDEMPLO, an FDA-approved RNAi-based therapy for familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by extremely elevated triglyceride levels.
The U.S. launch initiated in late 2025 has gained traction, with over 400 prescriptions written within approximately five months and a patient base predominantly naive to similar APOC3 inhibitors.
The company’s pricing strategy—set at a wholesale acquisition cost (WAC) of $45,000 annually, a premium over competitors—is supported by clinical data signaling superior triglyceride reduction, safety, and dosing convenience.


Arrowhead Pharmaceuticals’ $45,000 REDEMPLO Launch: Can RNAi Scale Beyond Rare Disease?

<ul>
<li>Arrowhead Pharmaceuticals has reported its financial and operational performance for the fiscal year ending September 30, 2025, during a conference call.</li>
<li>The company achieved notable milestones, including the FDA approval of REDEMPLO, its first FDA-approved drug.</li>
<li>This approval marks Arrowhead's transition into a commercial-stage company, providing a treatment for familial chylomicronemia syndrome (FCS), a rare condition characterized by extremely high triglyceride levels leading to pancreatitis.</li>
</ul>


Arrowhead Pharmaceuticals has reported its financial and operational performance for the fiscal year ending September 30, 2025, during a conference call.
The company achieved notable milestones, including the FDA approval of REDEMPLO, its first FDA-approved drug.
This approval marks Arrowhead's transition into a commercial-stage company, providing a treatment for familial chylomicronemia syndrome (FCS), a rare condition characterized by extremely high triglyceride levels leading to pancreatitis.


Arrowhead Pharmaceuticals Lands a Blockbuster Novartis Deal—Is This a $2 Billion Game Changer?

<ul>
<li>2021 saw a significant jump in RNA based trials. Large sequencing projects and the success of mRNA COVID-19 vaccines should drive the growth of the global RNA therapeutics market. </li>
<li>Our analysis suggests that <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna Inc (MRNA US)</a> , <a href="https://www.smartkarma.com/entities/vertex-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:4864:1" rel="noopener">Vertex Pharmaceuticals (VRTX US),</a> <a href="https://www.smartkarma.com/entities/incyte-corp" target="_blank" data-smartkarma-citation="entities:20576:1" rel="noopener">Incyte Corp (INCY US), </a><a href="https://www.smartkarma.com/entities/alnylam-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:2191:1" rel="noopener">Alnylam Pharmaceuticals (ALNY US), </a><a href="https://www.smartkarma.com/entities/isis-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:7017:1" rel="noopener">Ionis Pharmaceuticals (IONS US)</a> lead in RNA therapy related innovations.</li>
<li>R&amp;D collaboration, licensing deals, strategic investments and buyouts between RNA specialists and big pharma will increase as sitting on the sidelines might no longer be an option.</li>
</ul>


2021 saw a significant jump in RNA based trials. Large sequencing projects and the success of mRNA COVID-19 vaccines should drive the growth of the global RNA therapeutics market. 
Our analysis suggests that Moderna Inc (MRNA US) , Vertex Pharmaceuticals (VRTX US), Incyte Corp (INCY US), Alnylam Pharmaceuticals (ALNY US), Ionis Pharmaceuticals (IONS US) lead in RNA therapy related innovations.
R&amp;D collaboration, licensing deals, strategic investments and buyouts between RNA specialists and big pharma will increase as sitting on the sidelines might no longer be an option.


Data Mining Technical Publications to Rank the Innovators in RNA Therapeutics

United States

Arrowhead Pharmaceuticals, Inc. operates as a biotechnology company. The Company develops medicines that treat intractable diseases by silencing the genes. Arrowhead Pharmaceuticals offers its services in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Arrowhead Pharmaceuticals (ARWR US)

Arrowhead Pharmaceuticals & Madrigal — Strategic Partnerships Broaden The RNAi Growth Engine!

Arrowhead Pharmaceuticals reported its fiscal third quarter results for 2026, highlighting significant developments primarily centered on...

Baptista Research

Who Are Leading the Charge in the RNAissance of Medicine

RNA therapeutics: We analyze the field and spotlight top players driving this precision medicine, for tackling rare diseases with innovative solutions

Pyari Menon

Arrowhead Pharmaceuticals’ $45,000 REDEMPLO Launch: Can RNAi Scale Beyond Rare Disease?

The U.S. launch initiated in late 2025 has gained traction, with over 400 prescriptions written within approximately five months and a patient base...

Baptista Research

Arrowhead Pharmaceuticals Lands a Blockbuster Novartis Deal—Is This a $2 Billion Game Changer?

Arrowhead Pharmaceuticals has reported its financial and operational performance for the fiscal year ending September 30, 2025, during a conference...

Baptista Research

Data Mining Technical Publications to Rank the Innovators in RNA Therapeutics

Specialists lead the RNA intellectual property ecosystem but may still need big pharma to bring new treatments to market making the space ripe for...

Pyari Menon

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)